7-Hydroxystaurosporine
- Generic Name
- 7-Hydroxystaurosporine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C28H26N4O4
- CAS Number
- 112953-11-4
- Unique Ingredient Identifier
- 7BU5H4V94A
- Associated Conditions
- -
- Associated Therapies
- -
7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes
- Conditions
- Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myelomonocytic Leukemia (M4)Adult Acute Promyelocytic Leukemia (M3)Adult Erythroleukemia (M6a)Adult Pure Erythroid Leukemia (M6b)Blastic Phase Chronic Myelogenous LeukemiaRecurrent Adult Acute Lymphoblastic LeukemiaSecondary Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2006-03-13
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00301938
- Locations
- πΊπΈ
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-12-09
- Last Posted Date
- 2018-07-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 19
- Registration Number
- NCT00098956
- Locations
- π¨π¦
Princess Margaret Hospital Phase 2 Consortium, Toronto, Ontario, Canada
UCN-01 in Treating Patients With Advanced Cancer
- Conditions
- Locations
- πΊπΈ
Johns Hopkins Oncology Center, Baltimore, Maryland, United States
UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
- Conditions
- First Posted Date
- 2003-11-06
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- University Health Network, Toronto
- Registration Number
- NCT00072267
- Locations
- π¨π¦
Cancer Care Ontario-London Regional Cancer Centre, London, Ontario, Canada
π¨π¦Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, Canada
π¨π¦Princess Margaret Hospital, Toronto, Ontario, Canada
A Phase II Study of UCN-01 in Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2003-11-06
- Last Posted Date
- 2015-03-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 17
- Registration Number
- NCT00072189
- Locations
- πΊπΈ
UC Davis Cancer Center, Sacramento, California, United States
UCN-01 and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors
- Conditions
- First Posted Date
- 2003-05-30
- Last Posted Date
- 2010-01-15
- Lead Sponsor
- City of Hope Medical Center
- Registration Number
- NCT00006464
- Locations
- πΊπΈ
City of Hope Medical Group, Pasadena, California, United States
πΊπΈNorris Cotton Cancer Center, Lebanon, New Hampshire, United States
πΊπΈUSC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
Fluorouracil Plus UCN-01 in Treating Patients With Advanced or Refractory Solid Tumors
- Conditions
- First Posted Date
- 2003-05-08
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00004059
- Locations
- πΊπΈ
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
- Conditions
- Advanced Adult Primary Liver CancerRecurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal CavityRecurrent Extrahepatic Bile Duct CancerRecurrent Gallbladder CancerRecurrent Gastric CancerRecurrent Gastrointestinal Carcinoid TumorRecurrent Inverted Papilloma of the Paranasal Sinus and Nasal CavityCarcinoma of the AppendixGastrointestinal Stromal TumorEstrogen Receptor-negative Breast Cancer
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 41
- Registration Number
- NCT00031681
- Locations
- πΊπΈ
University of Virginia, Charlottesville, Virginia, United States
7-hydroxystaurosporine and Cisplatin in Treating Patients With Advanced Malignant Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00012194
- Locations
- πΊπΈ
Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
UCN-01 and Carboplatin in Treating Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-07-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT00036777
- Locations
- πΊπΈ
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.